129 related articles for article (PubMed ID: 10227448)
21. Amifostine (Ethyol): pharmacokinetic and pharmacodynamic effects in vivo.
van der Vijgh WJ; Korst AE
Eur J Cancer; 1996; 32A Suppl 4():S26-30. PubMed ID: 8976819
[TBL] [Abstract][Full Text] [Related]
22. Preclinical and clinical aspects on the use of amifostine as chemoprotector in neuroblastoma patients.
Fulda S; Fichtner I; Hero B; Berthold F
Med Pediatr Oncol; 2001 Jan; 36(1):199-202. PubMed ID: 11464883
[TBL] [Abstract][Full Text] [Related]
23. High-dose Cisplatin with amifostine: ototoxicity and pharmacokinetics.
Ekborn A; Hansson J; Ehrsson H; Eksborg S; Wallin I; Wagenius G; Laurell G
Laryngoscope; 2004 Sep; 114(9):1660-7. PubMed ID: 15475801
[TBL] [Abstract][Full Text] [Related]
24. Effects of amifostine (WR-2721, ethyol) on tumor growth and pharmacology of cytotoxic drugs in human xenotransplanted neuroblastomas.
Fichtner I; Lemm M; Becker M; Berthold F
Anticancer Drugs; 1997 Feb; 8(2):174-81. PubMed ID: 9073313
[TBL] [Abstract][Full Text] [Related]
25. Influence of single and multiple doses of amifostine on the efficacy and the pharmacokinetics of carboplatin in mice.
Korst AE; Boven E; van der Sterre ML; Fichtinger-Schepman AM; van der Vijgh WJ
Br J Cancer; 1997; 75(10):1439-46. PubMed ID: 9166935
[TBL] [Abstract][Full Text] [Related]
26. Time dependence of the selective modulation of cisplatin-induced nephrotoxicity by WR2721 in the mouse.
Treskes M; Boven E; Holwerda U; Pinedo HM; van der Vijgh WJ
Cancer Res; 1992 Apr; 52(8):2257-60. PubMed ID: 1313740
[TBL] [Abstract][Full Text] [Related]
27. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
28. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
29. Effects of cisplatin and amphotericin B on DNA adduct formation and toxicity in malignant glioma and normal tissues in rat.
Bergström P; Johnsson A; Cavallin-Ståhl E; Bergenheim T; Henriksson R
Eur J Cancer; 1997 Jan; 33(1):153-9. PubMed ID: 9071915
[TBL] [Abstract][Full Text] [Related]
30. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
Korst AE; van der Sterre ML; Eeltink CM; Fichtinger-Schepman AM; Vermorken JB; van der Vijgh WJ
Clin Cancer Res; 1997 May; 3(5):697-703. PubMed ID: 9815738
[TBL] [Abstract][Full Text] [Related]
32. American Society of Clinical Oncology clinical practice guidelines for the use of chemotherapy and radiotherapy protectants.
Hensley ML; Schuchter LM; Lindley C; Meropol NJ; Cohen GI; Broder G; Gradishar WJ; Green DM; Langdon RJ; Mitchell RB; Negrin R; Szatrowski TP; Thigpen JT; Von Hoff D; Wasserman TH; Winer EP; Pfister DG
J Clin Oncol; 1999 Oct; 17(10):3333-55. PubMed ID: 10506637
[TBL] [Abstract][Full Text] [Related]
33. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin and amifostine for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of arm II of Radiation Therapy Oncology Group (RTOG) 0116.
Small W; Winter K; Levenback C; Iyer R; Hymes SR; Jhingran A; Gaffney D; Erickson B; Greven K
Int J Gynecol Cancer; 2011 Oct; 21(7):1266-75. PubMed ID: 21892091
[TBL] [Abstract][Full Text] [Related]
34. WR-2721: inhibitor of cisplatin-induced micronuclei.
Mazur L; Czyzewska A; Augustynek A
Teratog Carcinog Mutagen; 2000; 20(6):349-56. PubMed ID: 11074519
[TBL] [Abstract][Full Text] [Related]
35. Amifostine protects against chemotherapy-induced neurotoxicity: an in vitro investigation.
Verstappen CC; Postma TJ; Geldof AA; Heimans JJ
Anticancer Res; 2004; 24(4):2337-41. PubMed ID: 15330181
[TBL] [Abstract][Full Text] [Related]
36. Chemoprotectants: a review of their clinical pharmacology and therapeutic efficacy.
Links M; Lewis C
Drugs; 1999 Mar; 57(3):293-308. PubMed ID: 10193684
[TBL] [Abstract][Full Text] [Related]
37. Protective effects of amifostine, curcumin, and melatonin against cisplatin-induced acute kidney injury.
Mercantepe F; Mercantepe T; Topcu A; Yılmaz A; Tumkaya L
Naunyn Schmiedebergs Arch Pharmacol; 2018 Sep; 391(9):915-931. PubMed ID: 29860655
[TBL] [Abstract][Full Text] [Related]
38. [Protective effect of amifostine on cisplatin-induced nephrotoxicity and its mechanism].
Guo Y; Liu Y; Xu LG; Guo MY
Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):8-12. PubMed ID: 16737611
[TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts.
Johnsson A; Olsson C; Nygren O; Nilsson M; Seiving B; Cavallin-Stahl E
Cancer Chemother Pharmacol; 1995; 37(1-2):23-31. PubMed ID: 7497593
[TBL] [Abstract][Full Text] [Related]
40. Improvement of the in vitro safety profile and cytoprotective efficacy of amifostine against chemotherapy by PEGylation strategy.
Yang X; Ding Y; Ji T; Zhao X; Wang H; Zhao X; Zhao R; Wei J; Qi S; Nie G
Biochem Pharmacol; 2016 May; 108():11-21. PubMed ID: 26944193
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
